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Two recent studies on Nature Medicine and Nature Com-
munications reported the unusual roles of astrocytes in the 
brain, that is, release gamma-aminobutyric acid (GABA) 
and impair hippocampal memory in Alzheimer’s disease 
(AD). 
AD represents one common form of neurodegenerative 
diseases, and is characterized by progressive dementia. The 
pathological feature of an AD brain includes the appearance 
of amyloid plaques, fibrillary tangles and the associated loss 
of neurons. Neurophysiological and neurochemical exami-
nations reveal the failures of synaptic transmission (espe-
cially the cholinergic modulation), altered expression of 
transmitter receptors and changes in the excitatory/     
inhibitory balance of transmission.  
GABAergic transmission is the major type of inhibitory 
transmission in the brain, and accounts for 1/3 of all synap-
tic transmission. GABA is synthesized in neurons that ex-
press glutamic acid decarboxylase (GAD). The presynaptic 
spikes lead to the release of terminal vesicles and therefore 
the GABA onto the post-synaptic GABAA or GABAB re-
ceptors, contributing to the fast inotropic transmission 
through chloride channel, or slower metabotropic transmis-
sion through G-protein coupled potassium channel, respec-
tively. The GABA in the synaptic cleft is then transported to 
the presynaptic terminal for re-utilization, or glial cells for 
further metabolism. Due to the lack of GAD in glia, the 
GABA is converted into succinic semialdehyde or gluta-
mine in astrocyte, for instance.  
GABAergic transmission is found to be altered at differ-
ent stages of AD, in both animal models and human patient 
studies. The first line of evidence originated from radiolig-
ands of GABAA receptor agonists (such as benzodiazepine). 
The results suggested for well-preserved or mild loss of 
GABAA receptor binding site in hippocampus and cortical 
areas; while there is also evidence showing that the in-
creased binding site in temporal cortex is due to the gliosis 
and the expression of GABA receptors on the glial cells. 
The second line of the proof was the analyses of GABA 
receptor protein and mRNA on animal models of AD or 
postmortem brain samples from AD patients. For instance, 
the GABAA α1 subunit which is important for benzodiaze-
pine binding, was found to be reduced in hippocampus of 
AD brains; the levels for GABAA β2/3 subunits were found 
to be either preserved or slight decrease in different studies. 
Moreover, the AD pathological in postmortem hippocampus 
was correlated to the decreases in GABAB receptor R1 ex-
pression. GABA metabolism revealed by GAD function 
was also found to be impaired in different brain regions, 
including the cerebellum. The third line was the biochemi-
cal analyses of GABA concentration in the cortex and body 
fluids. The amount of GABA was found to be significantly 
decreased in temporal cortex and hippocampus from brains 
of AD patients, yet not well correlated to the neuropatho-
logical finding of plaques and tangles. The cerebrospinal 
fluid and plasma concentration of GABA are found to be 
reduced in AD patients as well. Recent advances of neu-
roimaging (such as magnetic resonance spectroscopy, MRS) 
further revealed the decreased GABA concentration at cer-
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tain brain regions in AD patients, such as parietal region.  
The presence of GABAergic transmission and the loss of 
GABAergic neurons therefore lead to the paradoxical ques-
tion that how GABAergic transmission changes in AD pro-
gression. This was recently answered by the fact that reac-
tive astrocytes express GAD and release GABA through 
bestrophin 1 (best1) channel. Astrocytes were found to ex-
press GAD in development, physiological and pathological 
conditions, as well as in human tissues. Indeed, tissue frac-
tionation analyses revealed that stronger GAD activities in 
brain tissues of mice model of AD was localized to glial 
synaptosomes from reactive astrocytes, compared to those 
of the wild-type mice. The mechanism of GABA release 
from astrocytes is found to be multiple, including the com-
mon intracellular calcium increase-mediated release, and 
through the best1 channel. Notably, astrocyte exhibits slow 
gliotransmission and lacks fast excitation; therefore, the 
GABA is continuously released once produced, contributing 
to the tonic inhibition on surrounding neurons in both hip-
pocampus and cerebellum. In the two recent studies, Jo et al. 
[1] and Wu et al. [2] reported that GABA released from 
reactive astrocytes contributes to the hippocampal depend-
ent memory formation, indicating a novel therapeutic target 
to alleviate AD behavioral syndromes.  
Jo et al. [1] identified the aberrant GABA release from 
reactive astrocytes in APP/PS1 mice model of AD, and that 
the GABA is released through best1 channel, which is in 
line with their previous results on GABA release from as-
trocytes through this channel. Interestingly, they found that 
reactive astrocytes in hippocampus express minimal level of 
GAD, and that GABA is instead synthesized by monoamine 
oxidase-B (MAO-B) through putrescine degradation [1]. 
With MAO-B inhibitors, the authors successfully removed 
the tonic GABA inhibition on dentate gyrus (DG) granule 
neurons, revealed by the restoration of presynaptic stimula-
tion-induced spike probability in these cells. Notably, the 
MAO-B inhibitor administration led to rescue of the im-
paired DG long-term potentiation (LTP), as well as the 
learning and memory ability in passive avoidance paradigm 
and Morris water maze in this mouse model of AD [1].  
Wu et al. [2] reported similar results with a different 
mice model of AD, the 5XFAD mice. They showed the in-
creased GABA content in hippocampus of post-mortem AD 
patient brains, in addition to the mice results [2]. However, 
instead of best1 channel, they reported upregulation of 
GAT3/4 on astrocytes as the upstream mechanism of en-
hanced GABA release, and increased expression of 
α5-GABAA receptors on DG granule cells as the increased 
downstream sensitivity to tonic inhibition, both of which 
contributed to the impaired DG LTP. The pharmacological 
applications of GAT3/4 inhibitor SNAP-5114 or 
α5-GABAA receptor inverse agonist L-655708 were found 
to ameliorate the working memory deficits in AD mice [2]. 
Notably, DG area has more A-beta plaque deposits com-
pared to other hippocampal regions, such as CA1. Such 
circuit-specific disruption of synaptic transmission during 
neurodegeneration is yet to be studied in the future.   
These studies provided the first link between astrocyte 
GABA release and the memory deficits in AD. Notably, 
both studies proved the therapeutic potential to alleviate the 
impaired memory with pharmacological compounds target-
ing the glial GABA production/release machinery. It will be 
interesting to examine if the GABAergic astrocytes ob-
served in DG contributes to alteration of brain functions in 
other brain regions, such as parietal lobe, endorhinal cortex 
and piriform cortex. It has been estimated that 80% of hip-
pocampal astrocytes contain GABA; in addition, most hu-
man astrocytes in culture express GAD and GABA metabo-
lizing enzymes. These data emphasized the importance of 
gliosis in reaction to neurodegeneration: in addition to their 
roles in neuroinflammation, reactive astrocytes participate 
in synaptic transmission directly by controlling the strength 
of tonic inhibition.  
Prior to the mechanistic discovery, GABAergic agonist 
or GABA transmission enhancer were found to treat the 
secondary symptoms (behavioral disruption) of AD. Inter-
estingly, the GABAergic imbalance in AD has been linked 
to the impaired adult neurogenesis in hippocampus, in 
Apolipoprotein E4 (apoE4) knock-in mice [3], as well as 
human amyloid precursor protein (hAPP) transgenic mice 
[4], respectively. The loss of GABAergic interneurons re-
sulted in the reduced maturation of new-born neurons in the 
DG, in consistency with the important roles of GABA in 
adult neurogenesis. Since adult generated neurons in hippo-
campus become DG granule cells, it will be very interesting 
to know if the impaired DG LTP is one downstream effect 
of impaired adult neurogenesis. It has been shown that re-
duction of adult neurogenesis influences the DG LTP and 
long-term depression. The addition of GABAergic astro-
cytes provided a new player in the relationship between 
adult neurogenesis impairment and AD [5].  
Collectively, Jo et al. [1] and Wu et al. [2] provided 
strong evidence linking GABA release from astrocytes to 
brain function changes in AD. Their results may serve as 
common mechanism under other neurodegenerative diseas-
es, and pave the way for further therapeutic efforts in 
searching for the novel pharmacological target, that is, re-
moving the “glial inhibition”.  
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